SCHEMBL6049236

SCHEMBL6049236

NC(=O)SCCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 5/20 0.64
CYP2D6 P10635 3/20 0.52
NPC1 O15118 1/20 0.52
CYP3A4 P08684 1/20 0.52
RAB9A P51151 1/20 0.52
HIF1A Q16665 1/20 0.52
IDO1 P14902 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
BLM P54132 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
CYP2A6 P11509 1/20 0.50
HTR2A P28223 1/20 0.50
TAAR1 Q96RJ0 1/20 0.50
LOXL2 Q9Y4K0 1/20 0.50
KEAP1 Q14145 1/20 0.50
LMNA P02545 2/20 0.48
NOS3 P29474 2/20 0.47
NOS2 P35228 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HDAC3 O15379 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20717979 0.90 NOS1 (0.68) NOS1NPC1RAB9ASMN1; SMN2CYP2A6
SCHEMBL1397310 0.80 IDO1 (0.65) NOS1IDO1TAAR1NOS3NOS2
Carbamic Acid SCHEMBL2222080 0.79 FFAR1 (0.62) NOS1SMN1; SMN2CYP2A6HTR2ATAAR1
Urea SCHEMBL2006220 0.79 FFAR1 (0.62) NOS1SMN1; SMN2CYP2A6HTR2ATAAR1
SCHEMBL8534052 0.78 NOS1 (0.53) NOS1NPC1RAB9AIDO1SMN1; SMN2
SCHEMBL6882189 0.78 ALDH1A1 (0.57) NOS1IDO1SMN1; SMN2CYP2A6HTR2A
SCHEMBL11686207 0.78 NOS1 (0.53) NOS1NPC1RAB9AIDO1SMN1; SMN2
SCHEMBL28338047 0.78 NOS1 (0.53) NOS1IDO1SMN1; SMN2CYP2A6HTR2A
SCHEMBL17434763 0.78 NOS1 (0.64) NOS1CYP2D6NPC1CYP3A4RAB9A
SCHEMBL29004556 0.78 IDO1 (0.61) NOS1NPC1IDO1SMN1; SMN2CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101914124-B Nucleoside phosphonate conjugates as anti HIV agents GILEAD SCIENCES INC 2012-07-18 CN disclosed
CN-101935333-A Nucleoside phosphonate conjugates as anti-hiv agent GILEAD SCIENCES INC 2011-01-05 CN disclosed
CN-101914124-A Nucleoside phosphonate conjugates as anti-hiv agent GILEAD SCIENCES INC 2010-12-15 CN disclosed
CN-101591281-A Phosphonate compounds having immunomodulatory activity GILEAD SCIENCES INC (US) 2009-12-02 CN disclosed
CN-101381379-A Kinase inhibitor phosphonate conjugates GILEAD SCIENCES INC (US) 2009-03-11 CN disclosed
CN-101027312-A Antiviral compounds GILEAD SCIENCES INC (US) 2007-08-29 CN disclosed
US-20060264480-A1 Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same SUH YOUNG G 2006-11-23 US disclosed
EP-1311477-A4 NOVEL THIOCARBAMIC ACID DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME PACIFIC CORP (KR) 2005-01-12 EP disclosed
US-20030203944-A1 Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same PACIFIC CORPORATION (KR) 2003-10-30 US disclosed
EP-1311477-A1 NOVEL THIOCARBAMIC ACID DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME PACIFIC CORPORATION (KR) 2003-05-21 EP disclosed
WO-2002016317-A1 NOVEL THIOCARBAMIC ACID DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME PACIFIC CORPORATION (KR) 2002-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264480-A1 Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same TRPV1, TRPA1, TRPV5 NOS1 950/4885CYP2D6 893/4885NPC1 2332/4885
US-20030203944-A1 Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same TRPV1, TRPA1, TRPV5 NOS1 950/4885CYP2D6 893/4885NPC1 2332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.